Skip to main content
Intended for healthcare professionals
[image]
•  Subscribe
•  Log In More
Log in via Institution
Log in via OpenAthens
Log in via AAO
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username *
Password *
Forgot your log in details?Register a new account?
Forgot your user name or password?
•  Basket
•  Search More
Search for this keyword
Advanced search
[image]
•  Latest content
•  Current issue
•  Archive
•  Browse by collection
•  Authors
•  About
Search for this keyword


Advanced search
•  Close More
Main menu
○  Latest content
○  Current issue
○  Archive
○  Browse by collection
○  Authors
○  About
•  Subscribe
•  Log in More
Log in via Institution
Log in via OpenAthens
Log in via AAO
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username *
Password *
Forgot your log in details?Register a new account?
Forgot your user name or password?
•  BMJ Journals
You are here
•  Home
•  Archive
•  Volume 87, Issue 1
•  Tacrolimus


Email alerts
Article Text
Article menu
•  Article
Text
•  Article
info
•  Citation
Tools
•  Share
•  Rapid Responses
•  Article
metrics
•  Alerts
[image]PDF
Letter
Tacrolimus
1. D B Lake,
2. T R G Poole
1. Frimley Park Hospital, Portsmouth Road, Camberley, Surrey
GU16 7UJ, UK
https://doi.org/10.1136/bjo.87.1.121
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link


below which will take you to the Copyright Clearance Center’s
RightsLink service. You will be able to get a quick price and instant
permission to reuse the content in many different ways.
•  tacrolimus
Tacrolimus (FK506) is a highly immunosuppressive agent, in
particular tacrolimus inhibits the formation of cytotoxic
lymphocytes which are mainly responsible for graft rejection. We
report only the second case of bilateral optic neuropathy associated
with tacrolimus.
Case report
A 38 year old man with cystic fibrosis underwent pancreatic
transplantation in 1999. He had been taking 4 mg of tacrolimus
twice daily since his transplantation, and had never previously
taken cyclosporin because of renal impairment.
He had previously complained of gradual deterioration in vision of
over 6 months duration, at which time he had been seen at another
centre where visual acuity was noted to be 6/36 improving to 6/24
with pinhole bilaterally. Six months …
View Full Text
Read the full text or download the PDF:
Subscribe
Log in 


Log in via Institution
Log in via OpenAthens
Log in via AAO
Log in using your username and password


For personal accounts OR managers of institutional accounts
Username *
Password *
Forgot your log in details?Register a new account?
Forgot your user name or password?
Read the full text or download the PDF:
Subscribe
Log in 


Log in via Institution
Log in via OpenAthens
Log in via AAO
Log in using your username and password


For personal accounts OR managers of institutional accounts
Username *
Password *
Forgot your log in details?Register a new account?
Forgot your user name or password?


•  Content
○  Latest content
○  Current issue
○  Archive


○  Browse by collection
○  Most read articles
○  Top cited articles
○  Responses
•  Journal
○  About
○  Editorial board
○  Sign up for email alerts
○  Subscribe
○  Thank you to our reviewers
•  Authors
○  Instructions for authors
○  Submit an article
○  Editorial policies
○  Open Access at BMJ
○  BMJ Author Hub
•  Help
○  Contact us
○  Reprints
○  Permissions
○  Advertising
○  Feedback form
•  RSS
•  Twitter
•  Facebook


•  Website Terms & Conditions
•  Privacy & Cookies
•  Contact BMJ
Cookie Settings
Online ISSN: 1468-2079Print ISSN: 0007-1161


Copyright © 2025 BMJ Publishing Group Ltd. All rights, including for text and
data mining, AI training, and similar technologies, are reserved.


